Zhejiang Orient Gene Biotech (688298) received a 'D' on Foreign Investors Rating for Jan 2021.

Jan 15, 2021 (China Knowledge) - Zhejiang Orient Gene Biotech (688298) received a 'D' on Foreign Investors Rating for Jan 2021. This lowest rating shows the company has no foreign investment, poor coverage in both domestic and foreign news, and very few or zero Chinese or English analysts’ coverage. In addition, its IR management does not meet professional standards.

In terms of foreign investors' (FI) holdings by percentage the company is rated poor as it has no foreign investors. The company’s FIs fund flows received a 'Not Rated' grade, indicating that it has received zero FI.

Investor relation (IR) management performance is rather inactive as the company received few or no visits considerable from analysts, fund managers, financial media or other financial institutions in the last 3 months.

Like most developed stock markets, the more a company covered by analysts the stronger the performance of a...